Primary Progressive Multiple Sclerosis Study

Primary progressive multiple sclerosis (PPMS) is a form of the chronic disease multiple sclerosis (MS). Most people with MS start out with a clinical course characterized by episodes or attacks (relapses) of neurologic dysfunction, which occur over many years. This is called the relapsing-remitting phase. Unlike the relapsing-remitting MS, symptoms of PPMS get steadily worse, and remissions generally do not occur.

Limited approved MS and PPMS therapies are currently available. Meridian is conducting a Phase 3 clinical trial for an investigational medication for people with PPMS.

Eligible participants…

• Must be age 18 to 65 and have a current diagnosis of primary progressive multiple sclerosis (PPMS)
• Must have two of the following:
  • Documented evidence of one or more T2-hyperintense MRI lesions characteristic of MS in one or more specific brain regions
  • Documented evidence of two or more T2-hyperintense MRI lesions in the spinal cord
  • Documented evidence of the presence of cerebrospinal fluid-specific oligoclonal bands (established by a historical lumbar puncture)
• Will receive compensation for study-related time
• Do not need insurance to join this study

For more information, complete the form on this page. After you submit your information, a Meridian enrollment specialist will call you to talk about the study. There is no obligation to join — you can decide if the study is right for you.

You can also talk to a Meridian enrollment specialist about this study by calling (912) 623-2240.